The study showed that cognitive abilities in patients in the early stages of the disease taking Lecanemab decreased by 27%.
Scientists have created a drug that slowed the rate of memory and cognitive decline in people with early stages of Alzheimer’s disease. This was reported by The Guardian.
Specifically, the drug, developed by Eisai and Biogen, showed a 27% reduction in cognitive impairment over 18 months. This was only a modest change in clinical outcomes, but it was the first time that a drug clearly changed the trajectory of the disease.
“This is a historic moment for dementia research because it is the first phase III trial of an Alzheimer’s drug in a generation to successfully slow cognitive decline,” said Susan Kohlhaas, director of Alzheimer’s disease research at UK.
It was noted that 1800 people took part in the study. The patients were given a drug called Lecanemab twice a week. This drug has been shown to reduce the amount of toxic plaque in the brain and slow the decline of memory and patients’ ability to perform daily tasks.
About one-fifth of patients experienced side effects, including cerebral edema or cerebral bleeding seen on a PET scan, with about three percent of patients experiencing symptomatic side effects.
The scientists emphasized that the findings support the hypothesis that the sticky plaques seen in the brains of dementia patients play an important role in brain cell damage and cognitive decline.
The ultimate effectiveness of the drug depends on whether patients on the drug maintain better dynamics after the first 18 months.
Eisai and Biogen are expected to apply for regulatory approval in the US and Europe before the end of this year.
It was previously reported that a native of Scotland helped scientists develop a test to detect Parkinson’s disease in the early stages.
Developed a microscope that allows you to see through the skull
News from Correspondent.net on Telegram. Subscribe to our channel Athletistic
Source: korrespondent
